In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1069-1073

  Piercy, T ^a   Steward, J ^a   Lever, M S ^a   Brooks, T J G ^a,b  

^a Dstl ^*  (United Kingdom)

^b HPA   (United Kingdom)

Author keywords

Chemotherapy; Fluoroquinolones; Murine; Quinolones; Tularaemia

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DEXAMETHASONE; GATIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRANCISELLA TULARENSIS; IMMUNE DEFICIENCY; IN VIVO STUDY; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOMES RESEARCH; RELAPSE; SURVIVAL RATE; TULAREMIA;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; FLUOROQUINOLONES; FRANCISELLA TULARENSIS; MICE; MICE, INBRED BALB C; QUINOLINES; SURVIVAL ANALYSIS; TULAREMIA;

EID: 29444433834     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki359     Document Type: Article

References (36)

1. McCoy GW, Chapin CW. Further observations of a plague-like disease of rodents with a preliminary note on the causative agent. Bacterium tularense. J Infect Dis 1912; 10: 61-72.
2. Dennis DT, Inglesby TV, Henderson DA et al. Tularemia as a biological weapon; medical and public health management. J Am Med Assoc 2001; 21: 2763-73.
3. Ellis J, Oyston PCF, Green M et al. Tularemia. Clin Microbiol Rev 2002; 15: 1-16.
4. Gurycova D. First isolation of Francisella tularensis subsp. tularensis in Europe. Eur J Epidemiol 1998; 14: 797-802.
5. Tarnvik A, Berglund L. Tularemia. Eur Respir J 2003; 21: 361-73.
6. Olsufijev NG, Emelyanova OS. Comparative study of strains of B. tularense in the Old and New World and their taxonomy. J Hyg Epidemiol Microbiol Immunol 1959; 3: 138-49.
7. Sjöstedt A. Family XVII. Francisellaceae, genus I. Francisella. In: Brenner DJ, ed. Bergey's Manual of Systematic Bacteriology. NY: Springer-Verlag, 2002.
8. Forsman M, Sandstrom G, Sjostedt A. Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of phylogeny of genus and for identification of strains by PCR. Int J Syst Bacteriol 1994; 44 Suppl 1: 38-46.
9. Jellison WL. Tularemia in North America. 1930-1974. Missoula, Montana: University of Montana, 1974.
10. Evans ME, Gregory DW, Schaffner W et al. Tularemia: A 30 year experience with 88 cases. Medicine 1985; 64: 251-69.
11. Dienst FT. Tularemia: A perusal of three hundred and thirty-nine cases. J La State Med Soc 1963; 115: 114-27.
12. Berson RC, Harwell AB. Streptomycin in the treatment of tularemia. Am J Med Sci 1948; 215: 243-9.
13. Maurin M, Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 2001; 45: 2977-86.
14. Sawyer WD, Dangerfield HG, Hogge AL et al. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev 1966; 30: 542-8.
15. Mason WL, Eigelsbach HT, Little SF et al. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis 1980; 121: 39-45.
16. Sanders CV, Hahn R. Analysis of 106 cases of tularemia. J La State Med Soc 1968; 120: 391-3.
17. Overholt EL, Tigertt WD, Kadull PJ et al. An analysis of forty-two cases of laboratory-acquired tularemia. Am J Med 1961; 30: 785-806.
18. Enderlin G, Morales L, Jacobs RF et al. Streptomycin and alternative agents for the treatment of tularemia: Review of the literature. Clin Infect Dis 1994; 19: 42-7.
19. Russell P, Eley SM, Fulop MJ et al. The efficacy of ciprofloxacin and doxycycline against experimental tularemia. J Antimicrob Chemother 1998; 41: 461-5.
20. Ikaheimo I, Syrjala H, Karhukorpi J et al. In vitro antibiotic susceptibility of Franciselle tularensis isolated from humans and animals. J Antimicrob Chemother 2000; 46: 287-90.
21. Di Ninno VL, Cherwonogrodzky JW. Liposome-encapsulated ciprofloxacin is effective in the protection and treatment of Balb/c mice against Francisella tularensis. J Infect Dis 1993; 168: 793-4.
22. Scheel O, Reiersen R. Treatment of tularemia with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1992; 11: 447-8.
23. Arav-Boger R. Cat-bite tularemia in a seventeen-year-old girl treated with ciprofloxacin. Pediatr Infect Dis J 2000; 19: 583-4.
24. Johansson A, Urich S, Chu M et al. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis 2002; 34: 327-30.
25. Steward J, Lever MS, Simpson AJH et al. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother 2004: 54: 95-9.
26. Hartley MG, Green M, Choules G et al. Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infect Immun 2004; 72 Suppl 7: 4109-13.
27. Petrie A, Watson P. Statistics for Veterinary and Animal Science, 1st edn. London: Blackwell Science, 2000.
28. Feldman KA. Tularemia. J Am Vet Med Assoc 2003; 222: 725-9.
29. Fortier AH, Green SJ, Polsinelli T et al. Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser 1994; 60: 349-61.
30. Finch RG, Greenwood D, Norrby SR et al. Aminoglycosides and aminocyclitols. In: Antibiotic and Chemotherapy, 8th edn. Edinburgh: Churchill Livingstone 2003; P155-84.
31. Morris T. Antibiotic therapeutics in laboratory animals. Lab Anim 1995; 29: 16-36.
32. Bristol-Myers Squibb. Gatifloxacin Package Insert. Princeton, NJ, USA: Bristol-Myers Squibb.
33. Medina E, Goldmann O, Toppel A et al. Survival of Streptococcus pyogenes within host phagocytic cells: A pathogenic mechanism for persistence and systemic invasion. J Infect Dis 2003; 187: 597-603.
34. White N, Dance D, Chaowagul W et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2: 697-71.
35. Pappas G, Solera B, Akritidis N et al. New approaches to antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005; 26: 101-5.
36. Scheel O, Hoel T, Sandvik T et al. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 1993; 101: 33-6.